A randomized multicenter comparison of basiliximab and muromonab (OKT3) in heart transplantation: SIMCOR study

Transplantation

Volumn 81, Issue 11, 2006, Pages 1542-1548

  Segovia, Javier ^a   Rodríguez Lambert, José L ^b   Crespo Leiro, Maria G ^c   Almenar, Luis ^d   Roig, Eulùlia ^e   Gómez Sánchez, Miguel A ^f   Lage, Ernesto ^g   Manito, Nicolas ^h   Alonso Pulpón, Luis ^a  

^a HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^b HOSPITAL UNIVERSITARIO CENTRAL DE ASTURIAS   (Spain)

^c HOSPITAL JUAN CANALEJO   (Spain)

^d HOSPITAL UNIVERSITARIO LA FE   (Spain)

^e HOSPITAL CLÍNIC   (Spain)

^f HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^g HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^h HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

Author keywords

Basiliximab; Heart transplantation; Induction therapy; Muromonab CD3; OKT3

Indexed keywords

BASILIXIMAB; CYCLOSPORIN A; HYDROCORTISONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PARACETAMOL; PREDNISONE; RANITIDINE;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; ASEPTIC MENINGITIS; CARDIAC GRAFT REJECTION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; FEVER; HEADACHE; HEART TRANSPLANTATION; HUMAN; HYPOTENSION; LUNG EDEMA; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; DRUG TOLERANCE; FEMALE; FEVER; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; HYPERTENSION; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUROMONAB-CD3; PULMONARY EDEMA; RECOMBINANT FUSION PROTEINS; TIME FACTORS; TREATMENT OUTCOME;

EID: 33745159699     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000209924.00229.e5     Document Type: Article

References (31)

1. Taylor DO, Edwards LB, Mohacsi PJ, et al. The Registry of the International Society for Heart and Lung Transplantation: twentieth official adult heart transplant report-2003. J Heart Lung Transplant 2003; 22: 616-624.
2. Lindenfeld JA, Miller GG, Shakar SF, et al. Drug therapy in the heart transplant recipient. Part I. Cardiac rejection and immunosuppressive drugs. Circulation 2004; 110: 3734-3740.
3. Kirklin JK, Bourge RC, White-Williams C, et al. Prophylactic therapy for rejection after cardiac transplantation: a comparison of rabbit antithymocyte globulin and OKT3. J Thoracic Cardiovasc Surg 1990; 99: 716-724.
4. Chatenoud L, Ferran C, Reuter A, et al. Systemic reaction to the anti-T-cell monoclonal antibody OKT3 in relation to serum levels of tumor necrosis factor and interferon-gamma [corrected]. N Engl J Med 1989; 320: 1420-1421.
5. Avery RK, Pappas PG. Heart transplantation. In: Kirklin JK, Young JB, McGiffin DC, eds. Infections after heart (and heart/lung) transplantation. New York: Churchill Livingstone; 2002: 521-586.
6. Swinnen LJ, Costanzo-Nordin MR, Fisher SG, et al. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac-transplant recipients. N Engl J Med 1990; 323: 1723-1728.
7. Merigan TC, Renlund DG, Keay S, et al. A controlled trial of ganciclovir to prevent cytomegalovirus disease after heart transplantation. N Eng J Med 1992; 326: 1182-1186.
8. Amlot PL, Rawlings E, Fernando ON, et al. Prolonged action of a chimeric interleukin-2 receptor (CD25) monoclonal antibody used in cadaveric renal transplantation. Transplantation 1995; 60: 748-756.
9. Kirkman RL, Barrett LV, Gaulton GN, Kelley VE, Ythier A, Strom TB. Administration of an anti-interleukin 2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 1985; 162: 358-362.
10. Kahan BD, Rajagopalan PR, Hall M. Reduction of the occurrence of acute cellular rejection among renal allograft recipients treated with basiliximab, a chimeric anti-interleukin-2-receptor monoclonal antibody: United States Simulect Renal Study Group. Transplantation 1999; 67: 276-284.
11. ter Meulen CG, Baan CC, Hene RJ, Hilbrands LB, Hoitsma AJ. Two doses of daclizumab are sufficient for prolonged interleukin-2Ralpha chain blockade. Transplantation 2001; 72: 1709-1710.
12. Nashan B, Moore R, Amlot P, Schmidt AG, Abeywickrama K, Soulillou JP. Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allogratt recipients: CHIB 201 International study group. Lancet 1997; 350: 1193-1198.
13. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: meta-analysis of randomised trials. BMJ 2003; 326: 789-791.
14. Pisani B, Mullen GM, Malinowska K, et al. Plasmapheresis with intravenous immunoglobulin G is effective in patients with elevated panel reactive antibodies prior to cardiac transplantation. J Heart Lung Transplant 1999; 18: 701-706.
15. Taylor DO, Edwards LB, Boucek MM, Trulock EP, Keck BM, Hertz MI. The Registry of the International Society for Heart and Lung Transplantation: twenty-first official adult heart transplant report-2004. J Heart Lung Transplant 2004; 23: 796-803.
16. Costanzo MR. New monoclonal antibodies. Curr Opin Cardiol 1996; 11: 204-207.
17. Morris RE. Mechanisms of action of new immunosuppressive drugs. Kidney Int Suppl 1996; 53: S26-S38.
18. Beniaminovitz A, Itescu S, Lietz K, et al. Prevention of rejection in cardiac transplantation by blockade of interleukin-2-receptor with a monoclonal antibody. N Engl J Med 2000; 342: 613-619.
19. Vicenti F, Kirkman R, Light S, et al. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation: Daclizumab Triple Therapy Study Group. N Engl J Med 1998; 338: 161-165.
20. Nashan B. Antibody induction therapy in renal transplant recipients receiving calcineurin-inhibitor immunosuppressive regimens: a comparative review. BioDrugs 2005; 19: 39-46.
21. Hershberger RE, Starling RC, Eisen HJ, et al. Daclizumab to prevent rejection after cardiac transplantation. N Engl J Med 2005; 352: 2673-2681.
22. Danesi R, del Tacca M. Hematologic toxicity of immunosuppressive treatment. Transplant Proc 2004; 36: 703-704.
23. Pisoni R, Ruggenenti P, Remuzzi G. Drug-induced thrombotic microangiopathy: incidence, prevention and management. Drug Safety 2001; 24: 491-501.
24. Morris-Stiff G, Evans M, Baboolal K, et al. Haemolytic uraemic syndrome associated with OKT3. Transpl Int 1996; 9: 522-523.
25. Mackie F, Verran D, Horvath J, Tiller D. Severe thrombocytopenia with OKT3 use for steroid-resistant rejection in a cadaveric renal transplant recipient. Nephrol Dial Transplant 1996; 11: 2378.
26. Kode R, Fa K, Chowdhury S, et al. Basiliximab plus low-dose cyclosporin versus OKT3 for induction immunosuppression following renal transplantation. Clin Transplant 2003; 17: 369-376.
27. Chowdhury S, Kode RK, Ranganna K, et al. Induction strategy using basiliximab combined with mycophenolate MMF and immediate low-dose cyclosporin is steroid sparing and more effective than OKT3. Transplant Proc 2001; 33: 1057-1058.
28. Kode RK, Kumar AM, Pankewycz O, et al. Simulect induction significantly decreases CMV infection in kidney recipients compared to OKT3. Transplant Proc 2001; 33: 1268-1269.
29. Hooks MA, Wade CS, Millikan WJ Jr, et al. Muromonab CD-3: a review of its pharmacology, pharmacokinetics and clinical use in transplantation. Pharmacotherapy 1991; 11: 26-37.
30. Haverty TP, Sanders M, Sheahan M. OKT3 treatment of cardiac allograft rejection. J Heart Lung Transplant 1993; 12: 591-598.
31. Chin C, Pittson S, Luikart H, et al. Induction therapy for pediatric and adult heart transplantation: comparison between OKT3 and daclizumab. Transplantation 2005; 80: 477-481.